Dai Seki, Aki Iijima Industry, Carra, Next Stage (6th)

※The above Calendar is only a plan and may change due to the company's circumstances.---------------------------------------January 6 (Monday) <1712> Dai Sekis <1997> Aki Iijima Industries <2789> Karura <3186> Nextage <7611> Haide Hidaka <9793> Dai Sekis-------------------------------

Fisco JapanJan 6 05:30

Kuraudia Holdings: Interim report

EDINETNov 28, 2024 12:26 · Announcements

Kuraudia Holdings: Financial Report - 48th Term (2023/09/01 - 2024/08/31)

EDINETNov 27, 2024 13:50 · Announcements

Stocks that moved the previous day part1 Senko HD, Gelbins, Gelbins, etc.

Stock Name <Code> 2nd day closing price ⇒ change from previous day * Daiseki<9793> 3645 -115. Operating profit for the previous period decreased by 5.4% and the first quarter decreased by 0.7%, leading to an expanded decline in profit. * Claudia<3607> 353 -2924 The financial results for the fiscal year ending August 2024 showed a significant underperformance, resulting in a reversal of declining profits. * PRISMBio<206A> 415 -39 Reports of extending the hand of partnership with Eisai and others led to a sharp rise in the previous day. Profit-taking sales are dominant today. * Senco HD<9069> 1276 +31 Favorable profit-taking sales today due to the effect of a tariff revision.

Fisco JapanOct 3, 2024 06:15

Claudia - significantly fell back, with a significant downward deviation in the August 2024 period, resulting in a reversal to a decrease in profits.

Claudia <3607> plunged significantly. It announced the financial results for the fiscal year ending August 24th. Operating profit was 0.34 billion yen, a 38.3% decrease from the previous period, significantly below the previous financial estimates of 0.6 billion yen. The increase in SG&A expenses due to M&A implementation became a factor contributing to the decline in revenue. In the cumulative third quarter, it secured an increase in profit of 0.85 billion yen, a 5.9% increase from the same period last year, making it perceived as a significantly lower-than-expected landing. For the fiscal year ending August 25, the forecast is for a significant increase of 31.7% to 0.45 billion yen.

Fisco JapanOct 2, 2024 12:31

October 1st [Today's investment strategy]

[Fisco Selected Brands] [Material Brands] Nexera Pharma <4565> ¥1226 (10/1) Drug discovery venture. Former Sosei Group. Subsidiary Nexera Pharma Japan has announced the conclusion of a partnership agreement with Otsuka Pharmaceutical <4507> regarding the distribution and sales of the insomnia treatment drug "Cubic Tablets" in Japan, and the termination of sales efforts with Takeda Pharmaceutical <4534>. Otsuka Pharmaceutical will now independently carry out distribution and sales activities in Japan. [Emerging Markets

Fisco JapanOct 2, 2024 07:37